“McLean, Va. – Driven by its responsibility to protect and promote public health, the U.S. Food and Drug Administration (FDA) ensures that patients and providers have timely and continued access to safe, effective, and high-quality medical products. To advance that mission, in October of 2017, the FDA’s Center for Drug Evaluation and Research (CDER) awarded Booz Allen Hamilton (NYSE: BAH) one of two spots on a competitive, $300 million Blanket Purchase Agreement (BPA) over seven years to support its implementation of a transformational Informatics Platform that will enable the Agency to bring life-saving drugs to market with greater speed and efficiency…” Source: boozallen.com. Read the full announcement here.
FDA Selects Booz Allen for Spot on $300M Award to Optimize Drug Review Management by Enhancing Informatics Platform
[related-post]
Innovation in Action: Advancing Government Health with Philips
FORUM is proud to partner with Philips for a series of articles on their groundbreaking innovations in health technology that serve public- and private sector citizens and service members. Please take a look to learn more about how Philips is advancing modern and efficient health care, while improving lives for generations to come.
Don’t Miss A Thing
Subscribe to our mailing list
